Treatment of bone metastases from breast cancer and myeloma with pamidronate
- 31 December 1991
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 27 (1), 37-41
- https://doi.org/10.1016/0277-5379(91)90056-j
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD)The Lancet, 1988
- REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENTThe Lancet, 1987
- A Parathyroid Hormone-Related Protein Implicated in Malignant Hypercalcemia: Cloning and ExpressionScience, 1987
- A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonateJournal of Bone and Mineral Research, 1986
- ABSORPTION OF ORAL DIPHOSPHONATE IN NORMAL SUBJECTSClinical Endocrinology, 1986
- Carcinoma of the Breast Metastatic to the SkeletonClinical Orthopaedics and Related Research, 1984
- LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASESThe Lancet, 1983
- Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple MyelomaMetabolic Bone Disease and Related Research, 1982
- Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.JCI Insight, 1980
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaThe New England Journal of Medicine, 1980